Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Sarah Boyce

Overview

Gender
female

In October 2019, Sarah Boyce joined Avidity as President and CEO, and she serves as a member of the board of directors. Ms. Boyce brings to Avidity extensive operational, commercial and leadership experience in the life sciences industry and has built global organizations, bringing a number of innovative therapies including Tegsedi®, Waylivra®, Soliris®, Gleevec® and Tasigna® to patients. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led the commercialization of the company’s rare disease products. Prior to joining Akcea in April 2018, Ms. Boyce held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Ms. Boyce currently serves as a member of the board of directors at Ligand, Inc and Berkeley Lights, Inc. She received a B.S. degree in microbiology from the University of Manchester, England.

Jobs

Number of Current Jobs
1
Sarah Boyce has 1 current jobs including President & CEO at Avidity Biosciences , .
Organization Name Title At Company Start Date End Date
Avidity Biosciences President & CEO Oct 1, 2019 Detail